It has been shown that anti-CCL2 antibodies blocking the effects of CCL2 such as reducing MDSC, increasing CD4+ and CD8+ T cell infiltration, and promoting IFNy secretion can enhance the tumor immune effect of PD-1 in treating lung cancer in mice [15]. This evidence concerns the gene CD8A and neoplasm.